Evidence map›Paper›PMID 34833892›Full record

ArticleMolecules (Basel, Switzerland)2021

Spectrally and Time-Resolved Fluorescence Imaging of 22-NBD-Cholesterol in Human Peripheral Blood Mononuclear Cells in Chronic Kidney Disease Patients.

Ingrid Lajdova, Livia Ovsonkova, Viera Spustova, Adrian Oksa, Dusan Chorvat, Anton Mateasik, Alzbeta Marcek Chorvatova

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ingrid LajdovaDepartment of Clinical and Experimental Pharmacology, Faculty of Medicine, Slovak Medical University, 83303 Bratislava, Slovakia.
Livia OvsonkovaDepartment of Biophotonics, International Laser Centre of the Slovak Centre of Scientific and Technical Information, 84104 Bratislava, Slovakia.
Viera SpustovaDepartment of Clinical and Experimental Pharmacology, Faculty of Medicine, Slovak Medical University, 83303 Bratislava, Slovakia.
Adrian OksaDepartment of Clinical and Experimental Pharmacology, Faculty of Medicine, Slovak Medical University, 83303 Bratislava, Slovakia.
Dusan ChorvatDepartment of Biophotonics, International Laser Centre of the Slovak Centre of Scientific and Technical Information, 84104 Bratislava, Slovakia.
Anton MateasikDepartment of Biophotonics, International Laser Centre of the Slovak Centre of Scientific and Technical Information, 84104 Bratislava, Slovakia.
Alzbeta Marcek ChorvatovaDepartment of Biophotonics, International Laser Centre of the Slovak Centre of Scientific and Technical Information, 84104 Bratislava, Slovakia.ORCID 0000-0002-8798-0624
Slovak Centre of Scientific and Technical Information · SKSlovak Medical University · SK

Funding

European Union's Horizon 2020 research and innovation programme grant agreement no 871124 Laserlab-Europe (Laserlab Europe V)Grant Agency of the Ministry of Education, Science, Research and Sports of the Slovak Republic VEGA 2/0070/21Supporting Operational Research and Development Program financed from the European Regional Development Fund "Center of Excellence of Environmental Health," ITMS no. 26240120033
6 · The paper itself

Abstract

The interaction of the fluorescent probe 22-NBD-cholesterol with membranes of human peripheral blood mononuclear cells (PBMC) was tested by time- and spectrally resolved fluorescence imaging to monitor the disturbance of lipid metabolism in chronic kidney disease (CKD) and its treatment with statins. Blood samples from healthy volunteers (HV) and CKD patients, either treated or untreated with statins, were compared. Spectral imaging was done using confocal microscopy at 16 spectral channels in response to 458 nm excitation. Time-resolved imaging was achieved by time-correlated single photon counting (TCSPC) following excitation at 475 nm. The fluorescence of 22-NBD-cholesterol was mostly integrated into plasmatic membrane and/or intracellular membrane but was missing from the nuclear region. The presence of two distinct spectral forms of 22-NBD-cholesterol was uncovered, with significant variations between studied groups. In addition, two fluorescence lifetime components were unmasked, changing in CKD patients treated with statins. The gathered results indicate that 22-NBD-cholesterol may serve as a tool to study changes in the lipid metabolism of patients with CKD to monitor the effect of statin treatment.

Indexed as

4-Chloro-7-nitrobenzofurazanCell MembraneCholesterolFluorescent DyesHealthy VolunteersHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIntracellular MembranesLeukocytes, MononuclearLipid MetabolismMicroscopy, ConfocalPilot ProjectsRenal Insufficiency, Chronic4-Chloro-7-nitrobenzofurazan7-nitrobenz-2-oxa-1,3-diazol-4-ylcholesterolCholesterolFluorescent DyesHydroxymethylglutaryl-CoA Reductase Inhibitors22-NBD-cholesterolCKD—chronic kidney diseaseFLIM—fluorescence lifetime imaging microscopyPBMC—peripheral blood mononuclear cellsspectrally resolved confocal microscopystatins

Identifiers

PMID34833892
PMCPMC8619048
OpenAlexW3213623798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.